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to view.Percutaneous Circulatory Assist Devices for High-Risk Coronary Intervention 229
Aung Myat, Niket Patel, Shana Tehrani, Adrian P. Banning, Simon R. Redwood,
Deepak L. BhattHigh-risk percutaneous coronary intervention reﬂects a multitude of patient, anatomic, and procedural
characteristics that can increase risk. The relative inability to withstand the hemodynamic sequelae
of ischemia, arrhythmia, reperfusion injury, or distal embolization of plaque serves as a common
foundation for this patient cohort. This enhanced susceptibility to circulatory collapse has
stimulated the development and use of the intra-aortic balloon pump, Impella, TandemHeart,
and extracorporeal membrane oxygenation. The authors discuss the physiology underpinning their
application. Thereafter, they appraise the evidence base investigating their use in high-risk coronary
intervention to determine which patients might beneﬁt most from their use.
SEE ADDITIONAL CONTENT ONLINECLINICAL RESEARCH
CORONARY Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention:
A Report From the NCDR (National Cardiovascular Data Registry)245Emmanouil S. Brilakis, Subhash Banerjee, Dimitri Karmpaliotis, William L. Lombardi,
Thomas T. Tsai, Kendrick A. Shunk, Kevin F. Kennedy, John A. Spertus,
David R. Holmes, Jr, J. Aaron GranthamBetween July 1, 2009, and March 31, 2013, chronic total occlusion (CTO) percutaneous coronary
intervention (PCI) represented 3.8% of the total PCI volume for stable coronary artery disease.
CTO PCI was associated with lower procedural success (59% vs. 96%, p < 0.001) and higher major
adverse cardiac event (1.6% vs. 0.8%, p < 0.001) rates. Multivariable analyses revealed several
characteristics (older age, current smoking, previous myocardial infarction, previous coronary artery
bypass graft, previous peripheral arterial disease, previous cardiac arrest, right coronary artery
CTO target vessel, and less operator experience) associated with a lower likelihood of CTO PCI
procedural success.n EDITORIAL COMMENT
Percutaneous Coronary Intervention for Chronic Total Occlusions:
The Power of Negative Thinking254John A. BittlCONTINUED ON PAGE A-23
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FEBRUARY 2015 VOLUME 8, NUMBER 2Coronary Computed Tomographic Prediction Rule for Time-Efﬁcient Guidewire Crossing
Through Chronic Total Occlusion: Insights From the CT-RECTOR Multicenter Registry
(Computed Tomography Registry of Chronic Total Occlusion Revascularization)257Maksymilian P. Opolski, Stephan Achenbach, Annika Schuhbäck, Andreas Rolf,
Helge Möllmann, Holger Nef, Johannes Rixe, Matthias Renker, Adam Witkowski,
Cezary Kepka, Claudia Walther, Christian Schlundt, Artur Debski, Michal Jakubczyk,
Christian W. HammThe multicenter CT-RECTOR (Computed Tomography Registry of Chronic Total Occlusion
Revascularization) is a registry based on 240 consecutive chronic total occlusion (CTO) lesions
with pre-procedural coronary computed tomography angiography (CCTA) data; it established a
simple and accurate CCTA model for predicting successful guidewire crossing within 30 min
through CTO. The proposed CCTA scoring system does not suffer from the limitations of
conventional angiography and thus has the potential to exceed the discriminatory performance
of the previously validated angiographic models. Clinicians may ﬁnd the CT-RECTOR score
particularly useful for predicting the time-efﬁcient percutaneous revascularization and thus
difﬁculty grading in CTO.n EDITORIAL COMMENT
Chronic Total Occlusion Percutaneous Coronary Intervention in 2014 Beyond the
J-CTO Score (Japanese Multicenter CTO Registry): Chance Favors the Prepared Mind268Dimitrios Karmpaliotis, Philip Green
Long-Term Survival Beneﬁt of Revascularization Compared With Medical Therapy
in Patients With Coronary Chronic Total Occlusion and Well-Developed
Collateral Circulation271Woo Jin Jang, Jeong Hoon Yang, Seung-Hyuk Choi, Young Bin Song, Joo-Yong Hahn,
Jin-Ho Choi, Wook Sung Kim, Young Tak Lee, Hyeon-Cheol GwonLittle is known about the clinical outcomes of patients with chronic total occlusion (CTO) and
abundant collateral. Jang et al. analyzed data from 738 patients with at least 1 CTO and Rentrop 3
grade collateral. Patients who underwent revascularization and medical therapy (revascularization
group) were compared with those who underwent medical therapy alone (medication group) in
terms of cardiac death and major adverse cardiac events (MACE). During follow-up duration, the
incidence of cardiac death and MACE were signiﬁcantly lower in the revascularization group
compared with the medication group. In patients with CTO and abundant collateral, aggressive
revascularization may reduce the risk of adverse cardiac events.n EDITORIAL COMMENT
Are We Ready for a New Paradigm Shift in Percutaneous Revascularization
of Chronically Occluded Vessels With Well-Developed Collaterals?
From Leaving ’Em All to Stenting ’Em All280Emanuele Barbato, William WijnsCONTINUED ON PAGE A-24
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FEBRUARY 2015 VOLUME 8, NUMBER 2Real-Time Ultrasound Guidance Facilitates Transradial Access:
RAUST (Radial Artery Access With Ultrasound Trial)283Arnold H. Seto, Jonathan S. Roberts, Mazen S. Abu-Fadel, Steven J. Czak, Faisal Latif,
Suresh P. Jain, Jaffar A. Raza, Aditya Mangla, Georgia Panagopoulos, Pranav M. Patel,
Morton J. Kern, Zoran LasicThe utility of routine ultrasound guidance for transradial cardiac catheterization was investigated in a
multicenter randomized trial of 698 patients. Ultrasound guidance improved the ﬁrst-pass success
rate (64.8% vs. 43.9%, p < 0.0001) and reduced the number of attempts required to access
(1.65 vs. 3.05, p < 0.0001), the time to achieve access (88 s vs. 108 s, p ¼ 0.006), and number
of difﬁcult procedures. Clinical complications, pain, and spasm were infrequent and comparable
between the groups. These results demonstrate that ultrasound guidance improves the success
and efﬁciency of transradial access.
Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic
Left Ventricular Dysfunction and Stunning Without a Detected Difference in
Myocardial Substrate Utilization292Liam M. McCormick, Stephen P. Hoole, Paul A. White, Philip A. Read, Richard G. Axell,
Sophie J. Clarke, Michael O’Sullivan, Nick E.J. West, David P. DutkaIt is recognized that the multiple episodes of supply ischemia that occur with balloon inﬂations
during percutaneous coronary interventions result in stunning and cumulative left ventricular
dysfunction. The cardioprotective properties of glucagon-like peptide-1 (GLP-1) may have potential
as a therapeutic adjunct to support the heart during myocardial ischemia. However, mechanisms
remain unclear. This study was therefore undertaken to provide some mechanistic insights into
GLP-1–related cardioprotection. Speciﬁcally, the authors sought to determine whether pre-treatment
with intravenous GLP-1(7-36) amide, commenced before an ischemic insult, protected the heart
during percutaneous coronary intervention and whether it was associated with changes in the
myocardial use of glucose.n EDITORIAL COMMENT
Prevention of Myocardial Stunning During Percutaneous Coronary Interventions:
Novel Insights From Pre-Treatment With Glucagon-Like Peptide-1302Brigitta C. BrottCONTINUED ON PAGE A-25
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FEBRUARY 2015 VOLUME 8, NUMBER 2Inter–Core Lab Variability in Analyzing Quantitative Coronary Angiography for
Bifurcation Lesions: A Post-Hoc Analysis of a Randomized Trial305Maik J. Grundeken, Yuki Ishibashi, Philippe Généreux, Laura LaSalle, Javaid Iqbal,
Joanna J. Wykrzykowska, Marie-Angèle Morel, Jan G. Tijssen, Robbert J. de Winter,
Chrysaﬁos Girasis, Hector M. Garcia-Garcia, Yoshinobu Onuma, Martin B. Leon,
Patrick W. SerruysInter–core lab variability in quantitative coronary angiography analysis of bifurcation lesions between
2 core labs was evaluated before and after alignment of the used methodology. Before alignment,
the mean difference between the core labs (bias) was large for all quantitative coronary
angiography parameters with wide 95% limits of agreement. The bias of the in-segment
percentage diameter stenosis of the side branch was 5.5% (95% limits of agreement: –26.7% to
37.8%). After reanalysis, the bias of the in-segment percentage diameter stenosis of the side
branch reduced to 1.8% (95% limits of agreement: –16.7% to 20.4%). These ﬁndings emphasize
the importance of using the same methodology among different core labs worldwide.
SEE ADDITIONAL CONTENT ONLINESTRUCTURAL Health Status After Transcatheter Aortic Valve Replacement in Patients at
Extreme Surgical Risk: Results From the CoreValve U.S. Trial315Ruben L. Osnabrugge, Suzanne V. Arnold, Matthew R. Reynolds, Elizabeth A. Magnuson,
Kaijun Wang, Vincent A. Gaudiani, Robert C. Stoler, Thomas A. Burdon, Neal Kleiman,
Michael J. Reardon, David H. Adams, Jeffrey J. Popma, David J. Cohen,
on behalf of the CoreValve U.S. Trial InvestigatorsFor many patients considering transcatheter aortic valve replacement (TAVR), improvement in
quality of life may be of even greater importance than prolonged survival. In this single-arm trial,
TAVR via the transfemoral approach with a self-expanding bioprosthesis resulted in substantial
improvements in both disease-speciﬁc and generic health-related quality of life, but there
remained a substantial minority of patients who died or had very poor quality of life despite TAVR.
Predictive models based on a combination of clinical factors as well as disability and frailty may
provide insight into the optimal patient population for which TAVR is beneﬁcial.
SEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-26
CONTENTS
PAGE A-26
FEBRUARY 2015 VOLUME 8, NUMBER 2Outcomes of Inoperable Symptomatic Aortic Stenosis Patients Not Undergoing
Aortic Valve Replacement: Insight Into the Impact of Balloon Aortic Valvuloplasty
From the PARTNER Trial (Placement of AoRtic TraNscathetER Valve Trial)324Samir Kapadia, William J. Stewart, William N. Anderson, Vasilis Babaliaros,
Ted Feldman, David J. Cohen, Pamela S. Douglas, Raj R. Makkar, Lars G. Svensson,
John G. Webb, S. Chiu Wong, David L. Brown, D. Craig Miller, Jeffrey W. Moses,
Craig R. Smith, Martin B. Leon, E. Murat TuzcuThis study reports clinical outcomes of inoperable symptomatic patients undergoing balloon aortic
valvuloplasty (BAV) in the PARTNER (Placement of AoRtic TraNscathetER Valves) trial. Three-
month survival and quality of life at 1 month were better for patients undergoing BAV compared
with medical management alone. This beneﬁt, however, was short-lived with equal survival and
quality of life at 1 year for patients with and without BAV. BAV for aortic stenosis patients who
cannot undergo aortic valve replacement is a useful short-term palliative therapy.
Prosthetic Valve Endocarditis After Transcatheter Valve Replacement:
A Systematic Review334Ignacio J. Amat-Santos, Henrique B. Ribeiro, Marina Urena, Ricardo Allende,
Christine Houde, Elisabeth Bédard, Jean Perron, Robert DeLarochellière,
Jean-Michel Paradis, Eric Dumont, Daniel Doyle, Siamak Mohammadi,
Mélanie Côté, José Alberto San Roman, Josep Rodés-CabauThe aim of this review is to describe the incidence, characteristics, predisposing factors, and
outcomes of prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement
(TAVR) or transcatheter pulmonary valve replacement (TPVR) through a systematic review of all
published cases. A total of 60 patients (32 TAVRs, 28 TPVRs) were identiﬁed. PVE occurred more
frequently among male patients, TAVR patients with very high baseline risk, and TPVR patients
with a stenotic (vs. regurgitation) conduit/valve. Typical microorganisms of PVE were responsible
for one-half of the cases, with enterococci and Staphylococcus aureus being predominant among
TAVR and TPVR patients, respectively. Although most cases were “early infective endocarditis,”
classic contaminant germs were found in <50% of TVR patients. Most TAVR patients were treated
medically despite a high-rate of complications such as local extension, embolism, and heart failure,
whereas most TPVR patients underwent surgery. The reported IE mortality rate was 34.4% and
7.1% in TAVR and TPVR patients, respectively.
SEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-27
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FEBRUARY 2015 VOLUME 8, NUMBER 2PERIPHERAL Early Experimental and Clinical Experience With a Focal Implant for
Lower Extremity Post-Angioplasty Dissection347Peter A. Schneider, Robert Giasolli, Adrian Ebner, Renu Virmani,
Juan F. GranadaThe Tack-It device (Intact Vascular, Inc., Wayne, Pennsylvania) provides focal treatment of
post–percutaneous transluminal balloon angioplasty (post-PTA) dissection of the lower extremity
arteries and avoids the use of stents. Preclinical and ﬁrst-in-human data are presented. Seven
swine underwent superﬁcial femoral artery device placement. Clinical study included 15 limbs with
25 lesions of the superﬁcial femoral, popliteal, and tibial arteries. Tack-It caused less inﬂammation
than stents in the preclinical study, reducing stenosis, neointimal thickness, and injury score. Post-
PTA dissection was resolved in 100% of lesions with 83.3% 1-year angiographic patency. Tack-It
minimized vessel injury in the preclinical study. Clinical use was safe and feasible, resulting in
resolution of dissection without stent placement.TRANSLATIONAL Efﬁcacy of Polymer Injection for Ischemic Mitral Regurgitation: Persistent Reduction
of Mitral Regurgitation and Attenuation of Left Ventricular Remodeling355Xin Zeng, Lin Zou, Robert A. Levine, J. Luis Guerrero, Mark D. Handschumacher,
Suzanne M. Sullivan, Gavin J.C. Braithwaite, James R. Stone, Jorge Solis,
Orhun K. Muratoglu, Gus J. Vlahakes, Judy HungThis study shows that localized polyvinyl-alcohol (PVA) injection has prolonged efﬁcacy after
injection into infarcted myocardium underlying the papillary muscles in a chronic ischemic mitral
regurgitation (IMR) sheep model. It persistently reduces MR severity without MR recurrence,
stabilizes the mitral valve–left ventricular (LV) spatial relationship, and more importantly
attenuates LV remodeling and maintains LV systolic function over 8 weeks after PVA injection.
These beneﬁts are not observed in the sham-operated control group after only saline injection
with the same follow-up period. These results suggest injection of PVA hydrogel into infarcted
myocardium provides an alternative approach to the treatment of IMR with maintained efﬁcacy
over time.n EDITORIAL COMMENT
What to Do About Ischemic Mitral Regurgitation? 364
Michael RagostaCONTINUED ON PAGE A-28
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FEBRUARY 2015 VOLUME 8, NUMBER 2IMAGES IN
INTERVENTIONWhen Collateral Damage Does Matter: Iatrogenic Ventricular Septal Rupture
After Percutaneous Coronary Intervention of the Left Anterior Descending Artery367Vincent Michiels, Martin J. Swaans, Bastiaan J. Sorgdrager, Rolf F. Veldkamp,
Robin H. Heijmen, Jurrien M. ten Berg
Transcatheter Closure of a Post-Myocardial Infarction Ventricular Septal
Rupture Using a Parachute Device369Daxin Zhou, Wenzhi Pan, Lihua Guan, Cuizhen Pan, Junbo Ge
n ONLINE FEATURE Avulsion of an Aortic Cusp During Aortic Balloon Valvuloplasty e15
Stavros Hadjimiltiades, Antonis Ziakas, George Kazinakis, Chrysovalantou Nikolaidou,
Kyriakos Anastasiadis, Haralambos Karvounis
n ONLINE FEATURE Left Main Coronary Embolization After Direct Current
Cardioversion for Persistent Atrial Flutter in the Absence of Detectable
Intracardiac Thrombie17Daniel Garcia, Mohammad Ansari, Jafﬁd S. Majjul, Elman M. Urbina,
Alexandre C. Ferreira, Cesar E. Mendoza
n ONLINE FEATURE First Reported Use of the Repositionable Lotus Valve
System for a Failing Surgical Aortic Bioprosthesise19Liam M. McCormick, Robert Gooley, Siobhan Lockwood, Ian T. Meredith
n ONLINE FEATURE Adenosine-Induced Vasospasticity in a Myocardial
Bridge.Endothelial Dysfunction?e21Ahmed Farag, Yahya Al-najjar, Jonas Eichhöfer
n ONLINE FEATURE Inferior Vena Cava Filter Thrombosis and Suprarenal
Caval Stenosis: A Double Whammye23Mohamad Alkhouli, Irfan Shaﬁ, Riyaz Bashir
n ONLINE FEATURE Transcatheter Lotus Valve Implantation in a Degenerated
Carpentier-Edwards Bioprosthesise27Nicolas M. Van Mieghem, Ramon Rodriguez-Olivares, Ben Ren, Mohamed Ouhlous,
Tjebbe W. Galema, Marcel L. Geleijnse, Arie-Pieter Kappetein, Peter P. de Jaegere
n ONLINE FEATURE First-in-Man Use of Intravascular Near-Infrared Spectroscopy in
the Carotid Arteries to Characterize Atherosclerotic Plaque Prior to Carotid Stentinge29Ryan D. Madder, Amr E. Abbas, Robert D. Saﬁan
n ONLINE FEATURE Successful Repositioning of a Direct Flow Medical 25-mm
Valve due to Acute Occlusion of Right Coronary Artery During Transcatheter
Aortic Valve Replacement Proceduree33Alexander Wolf, Thomas Schmitz, Azeem Latib, Christoph K. Naber
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
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